Latest News

Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access
Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access

May 17th 2024

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

Abrocitinib Demonstrates High Efficacy In Itch-Dominant Atopic Dermatitis
Abrocitinib Demonstrates High Efficacy In Itch-Dominant Atopic Dermatitis

May 14th 2024

Revealing Ruxolitinib’s Potential in Pediatric AD Treatment
Revealing Ruxolitinib’s Potential in Pediatric AD Treatment

May 13th 2024

Substantial Disease Burden is Positively Correlated With a Greater Number of Atopic Dermatitis Lesion Locations
Substantial Disease Burden is Positively Correlated With a Greater Number of Atopic Dermatitis Lesion Locations

May 10th 2024

© 2024 MJH Life Sciences

All rights reserved.